The Hippo pathway, p53 and cholesterol

References

• Silvente-Poirot S, Poirot M. Cholesterol metabolism and cancer: the good, the bad and the ugly. Curr Opin Pharmacol 2012; 12:673-6; PMID:23103112; http://dx.doi.org/10.1016/2.coph.2012.10.004
   PubMed Web of Science ®Google Scholar
• Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, LeRoith D. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 2013; 32:961-7; PMID:22469977; http://dx.doi.org/10.1038/2nc.2012.113
   PubMed Web of Science ®Google Scholar
• Liu J, Xu A, Lam KS, Wong NS, Chen J, Shepherd PR, Wang Y. Cholesterol-induced mammary tumorigenesis is enhanced by adiponectin deficiency: role of LDL receptor upregulation. Oncotarget 2013; 4:1804-18; PMID:24113220; http://dx.doi.org/10.18632/2ncotarget.1364
   PubMed Web of Science ®Google Scholar
• Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, Sotgia F, Lisanti MP, Frank PG. Role of cholesterol in the development and progression of breast cancer. Am J Pathol 2011; 178:402-12; PMID:21224077; http://dx.doi.org/10.1016/2.ajpath.2010.11.005
   PubMed Web of Science ®Google Scholar
• Boyd NF, McGuire V. Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer. J Natl Cancer Inst 1990; 82:460-8; PMID:2313717; http://dx.doi.org/10.1093/2nci/22.6.460
   PubMed Web of Science ®Google Scholar
• Ferraroni M, Gerber M, Decarli A, Richardson S, Marubini E, Crastes de Paulet P, Crastes de Paulet A, Pujol H. HDL-cholesterol and breast cancer: a joint study in northern Italy and southern France. Int J Epidemiol 1993; 22:772-80; PMID:8282454; http://dx.doi.org/10.1093/2je/22.5.772
   PubMed Web of Science ®Google Scholar
• Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 2011; 29:1592-8; PMID:21422422; http://dx.doi.org/10.1200/2CO.2010.31.5200
   PubMed Web of Science ®Google Scholar
• Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 2013; 342:1094-8; PMID:24288332; http://dx.doi.org/10.1126/2cience.1241908
   PubMed Web of Science ®Google Scholar
• Umetani M, Domoto H, Gormley AK, Yuhanna IS, Cummins CL, Javitt NB, Korach KS, Shaul PW, Mangelsdorf DJ. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 2007; 13:1185-92; PMID:17873880; http://dx.doi.org/10.1038/2m1641
   PubMed Web of Science ®Google Scholar
• Wu Q, Ishikawa T, Sirianni R, Tang H, McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep 2013; 5:637-45; PMID:24210818; http://dx.doi.org/10.1016/2.celrep.2013.10.006
   PubMed Web of Science ®Google Scholar
• Alvarez Sanz MC, Liu JM, Huang HH, Hawrylewicz EJ. Effect of dietary protein on morphologic development of rat mammary gland. J Natl Cancer Inst 1986; 77:477-87; PMID:3461209
   PubMedGoogle Scholar
• de Medina P, Paillasse MR, Segala G, Voisin M, Mhamdi L, Dalenc F, Lacroix-Triki M, Filleron T, Pont F, Saati TA, et al. Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties. Nat Commun 2013; 4:1840; PMID:23673625; http://dx.doi.org/10.1038/2comms2835
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89:331-40; PMID:9150132; http://dx.doi.org/10.1016/20092-8674(00)80213-5
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109:1125-31; PMID:11994399; http://dx.doi.org/10.1172/2CI0215593
   PubMed Web of Science ®Google Scholar
• Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, et al. Transcriptional activities of nuclear SREBP-1a, −1c, and −2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 2002; 43:1220-35; PMID:12177166
   PubMed Web of Science ®Google Scholar
• Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99:838-45; PMID:9062340; http://dx.doi.org/10.1172/2CI119247
   PubMed Web of Science ®Google Scholar
• Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996; 98:1575-84; PMID:8833906; http://dx.doi.org/10.1172/2CI118951
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Rawson RB, Brown MS. Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. Arch Biochem Biophys 2002; 397:139-48; PMID:11795864; http://dx.doi.org/10.1006/2bbi.2001.2615
   PubMed Web of Science ®Google Scholar
• Yu FX, Guan KL. The Hippo pathway: regulators and regulations. Genes Dev 2013; 27:355-71; PMID:23431053; http://dx.doi.org/10.1101/2ad.210773.112
   PubMed Web of Science ®Google Scholar
• Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21:2747-61; PMID:17974916; http://dx.doi.org/10.1101/2ad.1602907
   PubMed Web of Science ®Google Scholar
• Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130:1120-33; PMID:17889654; http://dx.doi.org/10.1016/2.cell.2007.07.019
   PubMed Web of Science ®Google Scholar
• Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(β-TRCP). Genes Dev 2010; 24:72-85; PMID:20048001; http://dx.doi.org/10.1101/2ad.1843810
   PubMed Web of Science ®Google Scholar
• Oren M, Aylon Y. The Hippo Signaling Pathway and Cancer. Springer Science & Business Media, New York, 2013
   Google Scholar
• Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14:359-70; PMID:24739573; http://dx.doi.org/10.1038/2rc3711
   PubMed Web of Science ®Google Scholar
• Aylon Y, Oren M. Chapter 1- The Paradox of p53: What, How and Why? In: G. Lozano AJL, ed. The p53 Protein: From Cell Regulation to Cancer. Cary, NC, USA: Cold Spring Harbor Laboratory Press, 2016
   Google Scholar
• Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-6; PMID:1614522; http://dx.doi.org/10.1038/258015a0
   PubMed Web of Science ®Google Scholar
• Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 2006; 20:2687-700; PMID:17015431; http://dx.doi.org/10.1101/2ad.1447006
   PubMed Web of Science ®Google Scholar
• Furth N, Bossel Ben-Moshe N, Pozniak Y, Porat Z, Geiger T, Domany E, Aylon Y, Oren M. Down-regulation of LATS kinases alters p53 to promote cell migration. Genes Dev 2015; 29:2325-30; PMID:26588988; http://dx.doi.org/10.1101/2ad.268185.115
   PubMed Web of Science ®Google Scholar
• Kostic C, Shaw PH. Isolation and characterization of sixteen novel p53 response genes. Oncogene 2000; 19:3978-87; PMID:10962554; http://dx.doi.org/10.1038/2j.onc.1203747
   PubMed Web of Science ®Google Scholar
• Kurinna S, Stratton SA, Coban Z, Schumacher JM, Grompe M, Duncan AW, Barton MC. p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. Hepatology 2013; 57:2004-13; PMID:23300120; http://dx.doi.org/10.1002/2ep.26233
   PubMed Web of Science ®Google Scholar
• Aylon Y, Sarver A, Tovy A, Ainbinder E, Oren M. Lats2 is critical for the pluripotency and proper differentiation of stem cells. Cell Death Differ 2014; 21:624-33; PMID:24413153; http://dx.doi.org/10.1038/2dd.2013.188
   PubMed Web of Science ®Google Scholar
• Aylon Y, Gershoni A, Rotkopf R, Biton IE, Porat Z, Koh AP, Sun X, Lee Y, Fiel MI, Hoshida Y, et al. The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes Dev 2016; 30:786-97; PMID:27013235; http://dx.doi.org/10.1101/2ad.274167.115
   PubMed Web of Science ®Google Scholar
• Yahagi N, Shimano H, Matsuzaka T, Sekiya M, Najima Y, Okazaki S, Okazaki H, Tamura Y, Iizuka Y, Inoue N, et al. p53 involvement in the pathogenesis of fatty liver disease. J Biol Chem 2004; 279:20571-5; PMID:14985341; http://dx.doi.org/10.1074/2bc.M400884200
   PubMed Web of Science ®Google Scholar
• Yahagi N, Shimano H, Matsuzaka T, Najima Y, Sekiya M, Nakagawa Y, Ide T, Tomita S, Okazaki H, Tamura Y, et al. p53 Activation in adipocytes of obese mice. J Biol Chem 2003; 278:25395-400; PMID:12734185; http://dx.doi.org/10.1074/2bc.M302364200
   PubMed Web of Science ®Google Scholar
• Gooley JJ, Chua EC. Diurnal regulation of lipid metabolism and applications of circadian lipidomics. J Genet Genomics 2014; 41:231-50; PMID:24894351; http://dx.doi.org/10.1016/2.jgg.2014.04.001
   PubMed Web of Science ®Google Scholar
• Pomerening JR, Sontag ED, Ferrell JE, Jr. Building a cell cycle oscillator: hysteresis and bistability in the activation of Cdc2. Nat Cell Biol 2003; 5:346-51; PMID:12629549; http://dx.doi.org/10.1038/2cb954
   PubMed Web of Science ®Google Scholar
• Ingolia N. Cell cycle: bistability is needed for robust cycling. Curr Biol 2005; 15:R961-3; PMID:16332526; http://dx.doi.org/10.1016/2.cub.2005.11.012
   PubMedGoogle Scholar
• Visser S, Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 2010; 9:3892-903; PMID:20935475; http://dx.doi.org/10.4161/2c.9.19.13386
   PubMed Web of Science ®Google Scholar
• Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, Lawrence JC, Jr, Kelly DP. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/2PARalpha regulatory pathway. Cell Metab 2006; 4:199-210; PMID:16950137; http://dx.doi.org/10.1016/2.cmet.2006.08.005
   PubMed Web of Science ®Google Scholar
• Assaily W, Rubinger DA, Wheaton K, Lin Y, Ma W, Xuan W, Brown-Endres L, Tsuchihara K, Mak TW, Benchimol S. ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol Cell 2011; 44:491-501; PMID:22055193; http://dx.doi.org/10.1016/2.molcel.2011.08.038
   PubMed Web of Science ®Google Scholar
• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2:a001008; PMID:20182602; http://dx.doi.org/10.1101/2shperspect.a001008
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012; 148:244-58; PMID:22265415; http://dx.doi.org/10.1016/2.cell.2011.12.017
   PubMed Web of Science ®Google Scholar
• Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 2015; 15:73-9; PMID:25592648; http://dx.doi.org/10.1038/2rc3876
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 2014; 16:357-66; PMID:24658687; http://dx.doi.org/10.1038/2cb2936
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, Zhang X, Zhang F, Chen H, Liu Y, et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A 2014; 111:E89-98; PMID:24367099; http://dx.doi.org/10.1073/2nas.1319190110
   PubMed Web of Science ®Google Scholar
• Taccioli C, Sorrentino G, Zannini A, Caroli J, Beneventano D, Anderlucci L, Lolli M, Bicciato S, Del Sal G. MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/2AZ in cancer cells. Oncotarget 2015; 6:38854-65; PMID:26513174
   PubMed Web of Science ®Google Scholar
• Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, Piazza S, Strano S, Del Sal G, Blandino G. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep 2016; 17:188-201; PMID:26691213; http://dx.doi.org/10.15252/2mbr.201540488
   PubMed Web of Science ®Google Scholar
• Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16:425-38; PMID:19878874; http://dx.doi.org/10.1016/2.ccr.2009.09.026
   PubMed Web of Science ®Google Scholar
• Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL, Chen J. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat Cell Biol 2015; 17:490-9; PMID:25751139; http://dx.doi.org/10.1038/2cb3113
   PubMed Web of Science ®Google Scholar
• Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, Lim DS, Guan KL. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol 2015; 17:500-10; PMID:25751140; http://dx.doi.org/10.1038/2cb3111
   PubMed Web of Science ®Google Scholar
• DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, Hsieh M, Zhu S, Asara JM, Zheng B, et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep 2014; 9:495-503; PMID:25373897; http://dx.doi.org/10.1016/2.celrep.2014.09.036
   PubMed Web of Science ®Google Scholar
• Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13:376-88; PMID:21459323; http://dx.doi.org/10.1016/2.cmet.2011.03.009
   PubMed Web of Science ®Google Scholar
• Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, McClatchey AI. Nf2/2erlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 2010; 24:1718-30; PMID:20675406; http://dx.doi.org/10.1101/2ad.1938710
   PubMed Web of Science ®Google Scholar
• Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD, Wang ZX. Long Noncoding RNA PVT1 Promotes Non-Small Cell lung cancer cell proliferation through epigenetically regulating LATS2 expression. Mol Cancer Ther 2016; 15:1082-94; PMID:26908628; http://dx.doi.org/10.1158/2535-7163.MCT-15-0707
   PubMed Web of Science ®Google Scholar
• Yao F, Zhou W, Zhong C, Fang W. LATS2 inhibits the activity of NF-kappa B signaling by disrupting the interaction between TAK1 and IKKbeta. Tumour Biol 2015; 36:7873-9; PMID:25946971; http://dx.doi.org/10.1007/213277-015-3362-x
   PubMed Web of Science ®Google Scholar
• Li J, Chen X, Ding X, Cheng Y, Zhao B, Lai ZC, Al Hezaimi K, Hakem R, Guan KL, Wang CY. LATS2 suppresses oncogenic wnt signaling by disrupting β-catenin/2CL9 interaction. Cell Rep 2013; 5:1650-63; PMID:24360964; http://dx.doi.org/10.1016/2.celrep.2013.11.037
   PubMed Web of Science ®Google Scholar
• Suzuki H, Yabuta N, Okada N, Torigata K, Aylon Y, Oren M, Nojima H. Lats2 phosphorylates p21/2DKN1A after UV irradiation and regulates apoptosis. J Cell Sci 2013; 126:4358-68; PMID:23886938; http://dx.doi.org/10.1242/2cs.125815
   PubMed Web of Science ®Google Scholar
• Zhang K, Rodriguez-Aznar E, Yabuta N, Owen RJ, Mingot JM, Nojima H, Nieto MA, Longmore GD. Lats2 kinase potentiates Snail1 activity by promoting nuclear retention upon phosphorylation. EMBO J 2012; 31:29-43; PMID:21952048; http://dx.doi.org/10.1038/2mboj.2011.357
   PubMed Web of Science ®Google Scholar
• Yabuta N, Mukai S, Okada N, Aylon Y, Nojima H. The tumor suppressor Lats2 is pivotal in Aurora A and Aurora B signaling during mitosis. Cell Cycle 2011; 10:2724-36; PMID:21822051; http://dx.doi.org/10.4161/2c.10.16.16873
   PubMed Web of Science ®Google Scholar
• Tschop K, Conery AR, Litovchick L, Decaprio JA, Settleman J, Harlow E, Dyson N. A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev 2011; 25:814-30; PMID:21498571; http://dx.doi.org/10.1101/2ad.2000211
   PubMed Web of Science ®Google Scholar
• Ganem NJ, Cornils H, Chiu SY, O'Rourke KP, Arnaud J, Yimlamai D, Thery M, Camargo FD, Pellman D. Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell 2014; 158:833-48; PMID:25126788; http://dx.doi.org/10.1016/2.cell.2014.06.029
   PubMed Web of Science ®Google Scholar
• Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, Oren M. Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene 2009; 28:4469-79; PMID:19855428; http://dx.doi.org/10.1038/2nc.2009.270
   PubMed Web of Science ®Google Scholar
• Aylon Y, Ofir-Rosenfeld Y, Yabuta N, Lapi E, Nojima H, Lu X, Oren M. The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev 2010; 24:2420-9; PMID:21041410; http://dx.doi.org/10.1101/2ad.1954410
   PubMed Web of Science ®Google Scholar
• Hirano Y, Yoshida M, Shimizu M, Sato R. Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem 2001; 276:36431-7; PMID:11477106; http://dx.doi.org/10.1074/2bc.M105200200
   PubMed Web of Science ®Google Scholar
• Hirano Y, Murata S, Tanaka K, Shimizu M, Sato R. Sterol regulatory element-binding proteins are negatively regulated through SUMO-1 modification independent of the ubiquitin/26 S proteasome pathway. J Biol Chem 2003; 278:16809-19; PMID:12615929; http://dx.doi.org/10.1074/2bc.M212448200
   PubMed Web of Science ®Google Scholar
• Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, Raver-Shapira N, Minsky N, Pirngruber J, Tarcic G, et al. The histone H2B-specific ubiquitin ligase RNF20/2BRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev 2008; 22:2664-76; PMID:18832071; http://dx.doi.org/10.1101/2ad.1703008
   PubMed Web of Science ®Google Scholar
• Kim J, Hake SB, Roeder RG. The human homolog of yeast BRE1 functions as a transcriptional coactivator through direct activator interactions. Mol Cell 2005; 20:759-70; PMID:16337599; http://dx.doi.org/10.1016/2.molcel.2005.11.012
   PubMed Web of Science ®Google Scholar
• Shema E, Kim J, Roeder RG, Oren M. RNF20 inhibits TFIIS-facilitated transcriptional elongation to suppress pro-oncogenic gene expression. Mol Cell 2011; 42:477-88; PMID:21596312; http://dx.doi.org/10.1016/2.molcel.2011.03.011
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee GY, Jang H, Choe SS, Koo SH, Kim JB. Ring finger protein20 regulates hepatic lipid metabolism through protein kinase A-dependent sterol regulatory element binding protein1c degradation. Hepatology 2014; 60:844-57; PMID:24425205; http://dx.doi.org/10.1002/2ep.27011
   PubMed Web of Science ®Google Scholar
• Wagner A. Energy constraints on the evolution of gene expression. Mol Biol Evol 2005; 22:1365-74; PMID:15758206; http://dx.doi.org/10.1093/2olbev/2si126
   PubMed Web of Science ®Google Scholar
• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12; PMID:18431400; http://dx.doi.org/10.1038/2rm2395
   PubMed Web of Science ®Google Scholar
• Zeng L, Skinner SO, Zong C, Sippy J, Feiss M, Golding I. Decision making at a subcellular level determines the outcome of bacteriophage infection. Cell 2010; 141:682-91; PMID:20478257; http://dx.doi.org/10.1016/2.cell.2010.03.034
   PubMed Web of Science ®Google Scholar
• Potelle S, Klein A, Foulquier F. Golgi post-translational modifications and associated diseases. J Inherit Metab Dis 2015; 38:741-51; PMID:25967285; http://dx.doi.org/10.1007/210545-015-9851-7
   PubMed Web of Science ®Google Scholar
• Deribe YL, Pawson T, Dikic I. Post-translational modifications in signal integration. Nat Struct Mol Biol 2010; 17:666-72; PMID:20495563; http://dx.doi.org/10.1038/2smb.1842
   PubMed Web of Science ®Google Scholar
• YA SNaK. Studying cell signal transduction with biomimetic point mutations. In:   DF, ed. Genetic Manipulation of DNA and Protein - Examples from Current Research: InTech, 2013
   Google Scholar
• Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004; 4:227-35; PMID:14993904; http://dx.doi.org/10.1038/2rc1300
   PubMed Web of Science ®Google Scholar
• Ricoult SJ, Yecies JL, Ben-Sahra I, Manning BD. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene 2016; 35:1250-60; PMID:26028026; http://dx.doi.org/10.1038/2nc.2015.179
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen K, Liu X, Huang L, Zhao D, Li L, Gao M, Pei D, Wang C, Liu X. Srebp-1 interacts with c-Myc to enhance somatic cell reprogramming. Stem Cells 2016; 34:83-92; PMID:26388522; http://dx.doi.org/10.1002/2tem.2209
   PubMed Web of Science ®Google Scholar
• Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006; 9:358-65; PMID:16778563; http://dx.doi.org/10.1097/21.mco.0000232894.28674.30
   PubMed Web of Science ®Google Scholar
• Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech 2013; 6:1353-63; PMID:24203995; http://dx.doi.org/10.1242/2mm.011338
   PubMed Web of Science ®Google Scholar
• Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004; 64:2212-21; PMID:15026365; http://dx.doi.org/10.1158/2008-5472.CAN-2148-2
   PubMed Web of Science ®Google Scholar
• Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2009; 2:ra82; PMID:20009104; http://dx.doi.org/10.1126/2cisignal.2000446
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res 2009; 50 Suppl:S15-27; PMID:18974038; http://dx.doi.org/10.1194/2lr.R800054-JLR200
   PubMed Web of Science ®Google Scholar
• Li X, Chen YT, Hu P, Huang WC. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther 2014; 13:855-66; PMID:24493696; http://dx.doi.org/10.1158/2535-7163.MCT-13-0797
   PubMed Web of Science ®Google Scholar
• Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins. Oncogene 2012; 31:4967-78; PMID:22310279; http://dx.doi.org/10.1038/2nc.2012.6
   PubMed Web of Science ®Google Scholar
• Gaist D, Hallas J, Friis S, Hansen S, Sorensen HT. Statin use and survival following glioblastoma multiforme. Cancer Epidemiol 2014; 38:722-7; PMID:25455652; http://dx.doi.org/10.1016/2.canep.2014.09.010
   PubMed Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 2011; 103:1461-8; PMID:21813413; http://dx.doi.org/10.1093/2nci/2jr291
   PubMed Web of Science ®Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367:1792-802; PMID:23134381; http://dx.doi.org/10.1056/2EJMoa1201735
   PubMed Web of Science ®Google Scholar
• Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30:609-41; PMID:15531395; http://dx.doi.org/10.1016/2.ctrv.2004.06.010
   PubMed Web of Science ®Google Scholar
• Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22:1139-48; PMID:11470741; http://dx.doi.org/10.1093/2arcin/22.8.1139
   PubMed Web of Science ®Google Scholar
• Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C, Distante A, De Caterina R. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res 2010; 86:311-20; PMID:19946014; http://dx.doi.org/10.1093/2vr/2vp375
   PubMed Web of Science ®Google Scholar
• Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 2012; 135:261-9; PMID:22806241; http://dx.doi.org/10.1007/210549-012-2154-x
   PubMed Web of Science ®Google Scholar
• McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI. Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age. Cancer Epidemiol Biomarkers Prev 2013; 22:1529-37; PMID:23833125; http://dx.doi.org/10.1158/2055-9965.EPI-13-0414
   PubMed Web of Science ®Google Scholar